You are accessing a medical content website
Are you a health professional?

 
Revista Española de Cardiología (English Edition) Revista Española de Cardiología (English Edition)
Rev Esp Cardiol. 2016;69:1083-7 - Vol. 69 Num.11 DOI: 10.1016/j.rec.2016.05.033

Challenges in Oral Lipid-lowering Therapy: Position Document of the Spanish Society of Cardiology

Manuel Anguita Sánchez a, Almudena Castro Conde b, Alberto Cordero Fort c, Xavier García-Moll Marimón d, Juan José Gómez Doblas e, José R. González-Juanatey f,, Rosa María Lidón Corbi g, José Luis López-Sendón b, José Mostaza Prieto h, Luis Rodríguez Padial i

a Servicio de Cardiología, Hospital Universitario Reina Sofía, Córdoba, Spain
b Servicio de Cardiología, Hospital Universitario La Paz, Madrid, Spain
c Servicio de Cardiología, Hospital Universitario de San Juan, San Juan de Alicante, Alicante, Spain
d Servicio de Cardiología, Hospital de la Santa Creu y Sant Pau, Barcelona, Spain
e Servicio de Cardiología, Hospital Universitario de Málaga, Málaga, Spain
f Servicio de Cardiología, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain
g Servicio de Cardiología, Hospital Universitario Vall d’Hebron, Barcelona, Spain
h Servicio de Cardiología, Hospital Carlos III, Madrid, Spain
i Servicio de Cardiología, Hospital Virgen de la Salud, Toledo, Spain

Keywords

Lipids and ischemic heart disease. PCSK9 inhibitors. Consensus document.

Abstract

Lipid-lowering therapy is one of the cornerstones of cardiovascular prevention and is one of the most effective strategies in the secondary prevention of ischemic heart disease. Nevertheless, the current treatment of lipid disorders, together with lifestyle changes, fails to achieve the targets recommended in clinical guidelines in a substantial proportion of patients. PCSK9 inhibitors have demonstrated safety and efficacy in the treatment of dyslipidemia. Due to their ability to reduce low-density lipoprotein cholesterol levels, these drugs have recently been approved for clinical use by Spanish regulatory agencies, with the aim of reducing cardiovascular risk in selected patient groups.

Article

You can access the full text of this article:

Members of the Spanish Society of Cardiology


Subscribers of Revista Española de Cardiología

You may purchase this article for 30.00 €

Buy Now
Subscribers of ScienceDirect

1885-5857/© 2016 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved